The retinoblastoma protein: Functions beyond the G1-S regulator

Current Drug Targets

Volumn 13, Issue 13, 2012, Pages 1622-1632

  Uchida, Chiharu ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cancer; Cell cycle; Cyclin dependent kinase; E2F; Inactivation; Retinoblastoma protein

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO [2, 3 D] PYRIMIDIN 7 ONE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; CYCLIN A; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; HISTONE DEACETYLASE; NUTLIN 3; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RETINOBLASTOMA PROTEIN; SUMO PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL AGING; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; DNA REPLICATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; G1 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; VIRUS INFECTION;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; G1 PHASE CELL CYCLE CHECKPOINTS; GENETIC VARIATION; HUMANS; NEOPLASMS; RETINOBLASTOMA PROTEIN; S PHASE;

EID: 84870201784     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803529938     Document Type: Article

References (166)

1. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
2. Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983; 305: 779-784.
3. Cavenee WK, Hansen MF, Nordenskjold M, et al. Genetic origin of mutations predisposing to retinoblastoma. Science 1985; 228: 501-503.
4. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643-646.
5. Dryja TP, Rapaport JM, Joyce JM, Petersen RA. Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas. Proc Natl Acad Sci U S A 1986; 83: 7391-7394.
6. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987; 235: 1394-1399.
7. Lee WH, Shew JY, Hong FD, et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987; 329: 642-645.
8. Horowitz JM, Park SH, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a infset of human tumor cells. Proc Natl Acad Sci USA 1990; 87: 2775-2779.
9. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002; 2: 910-917.
10. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112.
11. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
12. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-2262.
13. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000; 14: 2393-2409.
14. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10: 699-703.
15. Wu L, Timmers C, Maiti B, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature 2001; 414: 457-462.
16. Hatakeyama M, Weinberg RA. The role of RB in cell cycle control. Prog Cell Cycle Res 1995; 1: 9-19.
17. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 2000; 14: 804-816.
18. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992; 70: 993-1006.
19. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 1995; 92: 12146-1250.
20. Resnitzky D, Hengst L, Reed SI. Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol Cell Biol 1995; 15: 4347-4352.
21. Singh M, Krajewski M, Mikolajka A, Holak TA. Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences. J Biol Chem 2005; 280: 37868-37876.
22. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000; 25: 338-342.
23. Nielsen SJ, Schneider R, Bauer UM, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001; 412: 561-565.
24. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998; 391: 597-601.
25. Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell 1998; 92: 463-473.
26. Defeo-Jones D, Huang PS, Jones RE, et al. Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature 1991; 352: 251-254.
27. Fattaey AR, Helin K, Dembski MS, et al. Characterization of the retinoblastoma binding proteins RBP1 and RBP2. Oncogene 1993; 8: 3149-3156.
28. Kaelin WG, Krek W, Sellers WR, et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 1992; 70: 351-364.
29. Dunaief JL, Strober BE, Guha S, et al. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 1994; 79: 119-130.
30. Strober BE, Dunaief JL, Guha, Goff SP. Functional interactions between the hBRM/hBRG1 transcriptional activators and the pRB family of proteins. Mol Cell Biol 1996; 16: 1576-1583.
31. Pennaneach V, Salles-Passador I, Munshi A, et al. The large infunit of replication factor C promotes cell survival after DNA damage in an LxCxE motif- and Rb-dependent manner. Mol Cell 2001; 7: 715-727.
32. Sterner JM, Dew-Knight S, Musahl C, Kornbluth S, Horowitz JM. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. Mol Cell Biol 1998; 18: 2748-2757.
33. Numata Y, Ishihara S, Hasegawa N, Nozaki N, Ishimi Y. Interaction of human MCM2-7 proteins with TIM, TIPIN and Rb. J Biochem 2010; 147: 917-927.
34. Johnson EM, Chen PL, Krachmarov CP, et al. Association of human Pur with the retinoblastoma protein, Rb, regulates binding to the single-stranded DNA Pur a recognition element. J Biol Chem 1995; 270: 24352-24360.
35. Gladden AB, Diehl JA. The cyclin D1-dependent kinase associates with the pre-replication complex and modulates RB.MCM7 binding. J Biol Chem 2003; 278: 9754-9760.
36. Ishida S, Huang E, Zuzan H, et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001; 21: 4684-4699.
37. Ren B, Cam H, Takahashi Y, et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002; 16: 245-256.
38. Hsu JY, Reimann JD, Sørensen CS, Lukas J, Jackson PK. E2Fdependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat Cell Biol 2002; 4: 358-366.
39. Lehman NL, Tibshirani R, Hsu JY, et al. Oncogenic regulators and infstrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors. Am J Pathol 2007; 170: 1793-1805.
40. Hernando E, Nahlé Z, Juan G, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004; 430: 797-802.
41. Yu H. Regulation of APC-Cdc20 by the spindle checkpoint. Curr Opin Cell Biol 2002; 14: 706-714.
42. Coschi CH, Martens AL, Ritchie K, et al. Mitotic chromosome condensation mediated by the retinoblastoma protein is tumorsuppressive. Genes Dev 2010; 24: 1351-1363.
43. Manning AL, Longworth MS, Dyson NJ. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev 2010; 24: 1364-1376.
44. van Harn T, Foijer F, van Vugt M, et al. Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. Genes Dev 2010; 24: 1377-1388.
45. Bester AC, Roniger M, Oren YS, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 2011; 145: 435-446.
46. Foijer F, Wolthuis RM, Doodeman V, Medema RH, Riele H. Mitogen requirement for cell cycle progression in the absence ofpocket protein activity. Cancer Cell 2005; 8: 455-466.
47. Zheng L, Flesken-Nikitin A, Chen PL, Lee WH. Deficiency of Retinoblastoma gene in mouse embryonic stem cells leads to genetic instability. Cancer Res 2002; 62: 2498-2502.
48. Iovino F, Lentini L, Amato A, di Leonardo A. RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol Cancer 2006; 5: 38.
49. Amato A, Lentini L, Schillaci T, Iovino F, di Leonardo A. RNAi mediated acute depletion of retinoblastoma protein (pRb) promotesaneuploidy in human primary cells via micronuclei formation. BMC Cell Biol 2009; 10: 79.
50. Mayhew CN, Bosco EE, Fox SR, et al. Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer Res 2005; 65: 4568-4577.
51. Longworth MS, Herr A, Ji JY, Dyson NJ. RBF1 promotes chromatin condensation through a conserved interaction with the Condensin II protein dCAP-D3. Genes Dev 2008; 22: 1011-1024.
52. Cimini D. Merotelic kinetochore orientation, aneuploidy, and cancer. Biochim Biophys Acta 2008; 1786: 32-40.
53. Isaac CE, Francis SM, Martens AL, et al. The retinoblastoma proteinregulates pericentric heterochromatin. Mol Cell Biol 2006; 26: 3659-3671.
54. Christensen J, Agger K, Cloos PA, et al. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 2007; 128: 1063-1076.
55. Klose RJ, Yan Q, Tothova Z, et al. The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell 2007; 128: 889-900.
56. Benevolenskaya EV, Murray HL, Branton P, Young RA, Kaelin WG, Jr. Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell 2005; 18: 623-635.
57. Lin W, Cao J, Liu J, et al. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci USA 2011; 108: 13379-1386.
58. Bourgo RJ, Thangavel C, Ertel A, et al. RB restricts DNA damageinitiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Mol Cell 2011; 43: 663-672.
59. Francis SM, Chakrabarti S, Dick FA. A context-specific role for retinoblastoma protein-dependent negative growth control in suppressing mammary tumorigenesis. PLoS One 2011; 6: e16434.
60. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene- induced senescence. Oncogene 2008; 27: 2801-2809.
61. Narita M, N-nez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003; 113: 703-716.
62. Zhang XL, Fu WL, Zhao HX, Zhou LX, Huang JF, Wang JH. Molecular studies of loss of heterozygosity in Chinese sporadic retinoblastoma patients. Clin Chim Acta 2005; 358: 75-80.
63. Sage J, Miller AL, Pérez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003; 424: 223-228.
64. Chicas A, Wang X, Zhang C, et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 2010; 17: 376-387.
65. Litovchick L, Florens LA, Swanson SK, Washburn MP, DeCaprio JA. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev 2011; 25: 801-813.
66. Tschöp K, Conery AR, Litovchick L, et al. A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev 2011; 25: 814-830.
67. Li T, Santockyte R, Shen RF, et al. Expression of SUMO-2/3- induced senescence through p53-and pRB-medicated pathways. J Biol Chem 2006; 281: 36221-36227.
68. Ledl A, Schmidt D, Müller S. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene 2005; 24: 3810-3818.
69. Munro S, Khaire N, Inche A, Carr S, La Thangue NB. Lysine methylation regulates the pRb tumour suppressor protein. Oncogene 2010; 29: 2357-2367.
70. Saddic LA, West LE, Aslanian A, et al. Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem 2010; 285: 37733-37740.
71. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. P53- dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994; 371: 72-74.
72. Macleod KF, Hu Y, Jacks T. Loss of Rb activates both p53- dependent and independent cell death pathways in the developing mouse nervous system. EMBO J 1996; 15: 6178-6188.
73. Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell 1998; 2: 293-304.
74. Saavedra HI, Wu L, de Bruin A, et al. Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb. Cell Growth Differ 2002; 13: 215-225.
75. Moroni MC, Hickman ES, Lazzerini Denchi E, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001; 3: 552-58
76. Guo Z, Yikang S, Yoshida H, Mak TW, Zacksenhaus E. Inactivation of the retinoblastoma tumor suppressor induces apoptosis protease-activating factor-1 dependent and independent apoptotic pathways during embryogenesis. Cancer Res 2001; 61: 8395-8400.
77. Müller H, Bracken AP, Vernell R, et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 2001; 15: 267-285.
78. Stanelle J, Tu-Rapp H, Pützer BM. A novel mitochondrial protein DIP mediates E2F1-induced apoptosis independently of p53. Cell Death Differ 2005; 12: 347-357.
79. Irwin M, Marin MC, Phillips AC, et al. Role for p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000; 407: 645-648.
80. Stiewe T, Pützer BM. Role of the p53-homologue p73 in E2F1- induced apoptosis. Nat Genet 2000; 26: 464-469.
81. Young AP, Longmore GD. Ras protects Rb family null fibroblasts from cell death: a role for AP-1. J Biol Chem 2004; 279: 10931-10938.
82. Moon NS, Di Stefano L, Dyson N. A gradient of epidermal growth factor receptor signaling determines the sensitivity of rbf1 mutant cells to E2F-dependent apoptosis. Mol Cell Biol 2006; 26: 7601-7615.
83. Uchida C, Miwa S, Kitagawa K, et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J 2005; 24: 160-169.
84. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008; 13: 11-22.
85. Milet C, Rincheval-Arnold A, Mignotte B, Guénal I. The Drosophila retinoblastoma protein induces apoptosis in proliferating but not in post-mitotic cells. Cell Cycle 2010; 9: 97-103.
86. Ianari A, Natale T, Calo E, et al. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 2009; 15: 184-194.
87. Slack RS, El-Bizri H, Wong J, Belliveau DJ, Miller FD. A critical temporal requirement for the retinoblastoma protein family during neuronal determination. J Cell Biol 1998; 140: 1497-1509.
88. MacPherson D, Sage J, Crowley D, Trumpp A, Bronson RT, Jacks T. Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system. Mol Cell Biol 2003; 23: 1044-1053.
89. MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. Cell type-specific effects of Rb deletion in the murine retina. Genes Dev 2004; 18: 1681-1694.
90. Zhang J, Gray J, Wu L, et al. Rb regulates proliferation and rod photoreceptor development in the mouse retina. Nat Genet 2004; 36: 351-360.
91. Chen D, Livne-bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell 2004; 5: 539-551.
92. Vooijs M, te Riele H, van der Valk M, Berns A. Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding protein-expressing cells. Oncogene 2002; 21: 4635-4645.
93. Sellers WR, Novitch BG, Miyake S, et al. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev 1998; 12: 95-106.
94. Siddiqui H, Solomon DA, Gunawardena RW, Wang Y, Knudsen ES. Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol Cell Biol 2003; 23: 7719-7731.
95. Siddiqui H, Fox SR, Gunawardena RW, Knudsen ES. Loss of RB compromises specific heterochromatin modifications and modulates HP1alpha dynamics. J Cell Physiol 2007; 211: 131-137.
96. Novitch BG, Mulligan GJ, Jacks T, Lassar AB. Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle. J Cell Biol 1996; 135: 441-456.
97. Thomas DM, Carty SA, Piscopo DM, et al. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 2001; 8: 303-316.
98. Hagemeier C, Bannister AJ, Cook A, Kouzarides T. The activation domain of transcription factor PU.1 binds the retinoblastoma (RB) protein and the transcription factor TFIID in vitro: RB shows sequence similarity to TFIID and TFIIB. Proc Natl Acad Sci USA. 1993; 90: 1580-1584.
99. Friedman AD. Transcriptional regulation of granulocyte and monocyte development. Oncogene 2002; 21: 3377-390.
100. Kim YC, Kim SY, Mellado-Gil JM, et al. RB regulates pancreas development by stabilizing Pdx1. EMBO J 2011; 30: 1563-1576.
101. Chen PL, Riley DJ, Chen Y, Lee WH. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev 1996; 10: 2794-2804.
102. Nguyen DX, Baglia LA, Huang SM, Baker CM, McCance DJ. Acetylation regulates the differentiation-specific functions of the retinoblastoma protein. EMBO J 2004; 23: 1609-1618.
103. Puri PL, Iezzi S, Stiegler P, et al. Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis. Mol Cell 2001; 8: 885-897.
104. Zacksenhaus E, Jiang Z, Chung D, Marth JD, Phillips RA, Gallie BL. pRb controls proliferation, differentiation, and death of skeletal muscle cells and other lineages during embryogenesis. Genes Dev 1996; 10: 3051-3064.
105. Takahashi C, Bronson RT, Socolovsky M, et al. Rb and N-ras function together to control differentiation in the mouse. Mol Cell Biol 2003; 23: 5256-5268.
106. Camarda G, Siepi F, Pajalunga D, et al. A pRb-independent mechanism preserves the postmitotic state in terminally differentiated skeletal muscle cells. J Cell Biol 2004; 167: 417-423.
107. Huh MS, Parker MH, Scimè A, Parks R, Rudnicki MA. Rb is required for progression through myogenic differentiation but not maintenance of terminal differentiation. J Cell Biol 2004; 166: 865-876.
108. Pajcini KV, Corbel SY, Sage J, Pomerantz JH, Blau HM. Transient inactivation of Rb and ARF yields regenerative cells from postmitotic mammalian muscle. Cell Stem Cell 2010; 7: 198-213.
109. Fajas L, Egler V, Reiter R, et al. The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell 2002; 3: 903-910.
110. Thomas DM, Carty SA, Piscopo DM, et al. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 2001; 8: 303-316.
111. Calo E, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA. Rb regulates fate choice and lineage commitment in vivo. Nature 2010; 466: 1110-1114.
112. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 1996; 271: 8313-8320.
113. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 1997; 272: 12738-12746.
114. Kitagawa M, Higashi H, Jung HK, et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996; 15: 7060-7069.
115. Kozar K, Ciemerych MA, Rebel VI, et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004; 118: 477-491.
116. Brown VD, Phillips RA, Gallie BL. Cumulative effect of phosphorylation of pRB on regulation of E2F activity. Mol Cell Biol 1999; 19:3246-3256.
117. Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 1997; 17: 5771-5783.
118. 4 regulates retinoblastoma protein-mediated cell cycle arrest by sitespecific phosphorylation. Mol Biol Cell 1997; 8: 287-301.
119. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005; 24: 2776-2786.
120. Hashimoto Y, Kohri K, Kaneko Y, et al. Critical role for the 310 helix region of p57Kip2 in cyclin-dependent kinase 2 inhibition and growth suppression. J Biol Chem 1998; 273: 16544-165450.
121. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512.
122. Pei XH, Xiong Y. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 2005; 24: 2787-2795.
123. Binné UK, Classon MK, Dick FA, et al. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol 2007; 9: 225-232. Erratum in: Nat Cell Biol 2007; 9: 353.
124. Dasgupta P, Padmanabhan J, Chellappan S. Rb function in the apoptosis and senescence of non-neuronal and neuronal cells: role in oncogenesis. Curr Mol Med 2006; 6: 719-729.
125. Dasgupta P, Betts V, Rastogi S, et al. Direct binding of apoptosis signal-regulating kinase 1 to retinoblastoma protein: novel links between apoptotic signaling and cell cycle machinery. J Biol Chem 2004; 279: 38762-38769.
126. Nath N, Wang S, Betts V, Knudsen E, Chellappan S. Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases. Oncogene 2003; 22: 5986-5994.
127. Inoue Y, Kitagawa M, Taya Y. Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage. EMBO J 2007; 26: 2083-2093.
128. Medina DL, Toro MJ, Santisteban P. Somatostatin interferes with thyrotropin-induced G1-S transition mediated by cAMP-dependent protein kinase and phosphatidylinositol 3-kinase. Involvement of RhoA and cyclin E x cyclin-dependent kinase 2 complexes. J Biol Chem 2000; 275: 15549-15556.
129. Guo J, Sheng G, Warner BW. Epidermal growth factor-induced rapid retinoblastoma phosphorylation at Ser780 and Ser795 is mediated by ERK1/2 in small intestine epithelial cells. J Biol Chem 2005; 280: 35992-35998.
130. Mishra S, Melino G, Murphy LJ. Transglutaminase 2 kinase activity facilitates protein kinase A-induced phosphorylation of retinoblastoma protein. J Biol Chem 2007; 282: 18108-18115.
131. Dasgupta B, Milbrandt J. AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev Cell 2009; 16: 256-270.
132. Jänicke RU, Walker PA, Lin XY, Porter AG. Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 1996; 15: 6969-6978.
133. Fattman CL, Scott M Delach SM, Dou QP, Johnson DE. Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis. Oncogene 2001; 20: 2918-2926.
134. Simpson MT, MacLaurin JG, Xu D, et al. Caspase 3 deficiency rescues peripheral nervous system defect in retinoblastoma nullizygous mice. J Neurosci 2001; 21: 7089-7098.
135. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
136. Miwa S, Uchida C, Kitagawa K, et al. Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent manner. Biochem Biophys Res Commun 2006; 340: 54-61.
137. Sdek P, Ying H, Chang DL, et al. MDM2 promotes proteasomedependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 2005; 20: 699-708.
138. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26: 3453-3459.
139. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
140. Pomerantz J, Schreiber-Agus N, Liégeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723.
141. Honda R, Yasuda H. Association of p19Arf with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999; 18: 22-27.
142. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 2007; 39: 1476-1482.
143. Uchida C, Miwa S, Isobe T, et al. Effects of MdmX on Mdm2- mediated downregulation of pRB. FEBS Lett 2006; 580: 1753-1758.
144. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitinmediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-199.
145. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. P27Kip1 ubiquitination and degradation is regulated by the SCFSKP2complex through phosphorylated Thr187 in p27. Curr Biol 1999; 9: 661-664.
146. Nakayama K, Nagahama H, Minamishima YA, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication. EMBO J 2000; 19: 2069-2081.
147. Kip1 at G1 phase. Nat Cell Biol 2004; 6: 1229-1235.
148. Kip1. Cancer Res 2007; 67: 10789-10795.
149. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitinprotein ligase, promotes p53 degradation. Cell 2003; 112: 779-791.
150. Shimada M, Kitagawa K, Dobashi Y, et al. High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers. Cancer Sci 2009; 100: 866-872.
151. Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell 1989; 56: 67-75.
152. Tommasino M, Crawford L. Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays 1995; 17: 509-518.
153. Dahiya A, Gavin MR, Luo RX, Dean DC. Role of the LXCXE binding site in Rb function. Mol Cell Biol 2000; 20: 6799-6805.
154. Chauveinc L, Mosseri V, Quintana E, et al. Osteosarcoma following retinoblastoma: age at onset and latency period. Ophthalmic Genet 2001; 22: 77-88.
155. Kaye FJ, Harbour JW. For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors. J Natl Cancer Inst 2004; 96: 342-343.
156. Wikenheiser-Brokamp KA. Retinoblastoma regulatory pathway in lung cancer. Curr Mol Med 2006; 6: 783-793.
157. Towatari M, Adachi K, Kato H, Saito H. Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood 1991; 78: 2178-2181.
158. Sharma A, Yeow WS, Ertel A, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010; 120: 4478-4492.
159. Shen H, Maki CG. Curr Pharm Des. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des 2011; 17: 560-568.
160. Du W, Wu J, Walsh EM, Zhang Y, Chen CY, Xiao ZX. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3. J Biol Chem 2009; 284: 26315-26321.
161. Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011; 18: 333-345.
162. Ertel A, Dean JL, Rui H, et al. RB-pathway disruption in breast cancer: differential association with disease inftypes, diseasespecific prognosis and therapeutic response. Cell Cycle 2010; 9: 4153-4163.
163. Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclindependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012; 104: 476-487.
164. Aparicio A, Den RB, Knudsen KE. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol 2011; 8: 562-568.
165. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-698.
166. Gordon GM, Du W. Targeting Rb inactivation in cancers by synthetic lethality. Am J Cancer Res 2011; 1: 773-786.